The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma
Open accessAbstract
SUMMARY Kinases execute pivotal cellular functions and are therefore widely investigated as potential targets in anticancer treatment. Here we analyze the kinase gene expression profiles of various tumor types and reveal the wee1 kinase to be overexpressed in glioblastomas. We demonstrate that WEE1 is a major regulator of the G2 checkpoint in glioblastoma cells. Inhibition of WEE1 by siRNA or small molecular compound in cells exposed to DNA damaging agents results in abrogation of the G2 arrest, premature termination of DNA repair, and cell death. Importantly, we show that the small-molecule inhibitor of WEE1 sensitizes glioblastoma to ionizing radiation in vivo. Our results suggest that inhibition of WEE1 kinase holds potential as a therapeutic approach in treatment of glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 2×
“Efficacy of this strategy has been demonstrated (Agulnik et al., 2007; Lynch et al., 2004; Ravaud et al., 2008; Vieth et al., 2005; Zhang et al., 2009).”
BackgroundThe protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationVogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“Therefore, abrogation of the G2 checkpoint, inducing premature mitotic entry and subsequent cell death, has emerged as a potential therapeutic strategy (Kawabe, 2004; Vogelstein et al., 2000).”
BackgroundGlioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo
Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N. M., Pastorino, S., Purow, B. W., Christopher, N., Zhang, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.030 · Cited by 2,311
A Perivascular Niche for Brain Tumor Stem Cells
Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., Oh, E. Y., Gaber, M. W., Finklestein, D., Allen, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.020 · Cited by 2,197
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., Lu, L., Irvin, D., Black, K. L., & Yu, J. S. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-67 · Cited by 1,790
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Regulation of DNA repair throughout the cell cycle
Branzei, D., & Foiani, M. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2351 · Cited by 1,228
Peri, S., Navarro, J. D., Amanchy, R., Kristiansen, T. Z., Jonnalagadda, C. K., Surendranath, V., Niranjan, V., Muthusamy, B., Gandhi, T. K. B., Gronborg, M., et al. (2003) · Genome Research · doi:10.1101/gr.1680803 · Cited by 1,089
(1999) · PubMed · Cited by 1,030
Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog
Russell, P., & Nurse, P. (1987) · Cell · doi:10.1016/0092-8674(87)90458-2 · Cited by 1,017
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Genetic control of cell size at cell division in yeast
Nurse, P. (1975) · Nature · doi:10.1038/256547a0 · Cited by 861
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
Reinhardt, H. C., Aslanian, A. S., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 596
A Hierarchy of Self-Renewing Tumor-Initiating Cell Types in Glioblastoma
Chen, R., Nishimura, M. C., Bumbaca, S. M., Kharbanda, S., Forrest, W. F., Kasman, I. M., Greve, J. M., Soriano, R. H., Gilmour, L. L., Rivers, C. S., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.049 · Cited by 544
MDC1 is required for the intra-S-phase DNA damage checkpoint
Goldberg, M., Stucki, M., Falck, J., D'Amours, D., Rahman, D., Pappin, D., Bartek, J., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature01445 · Cited by 506
Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15.
McGowan, C. H., & Russell, P. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05633.x · Cited by 493
DNA damage checkpoint control in cells exposed to ionizing radiation
Iliakis, G., Wang, Y., Guan, J., & Wang, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206682 · Cited by 476
M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCF β-TrCP
Watanabe, N., Arai, H., Nishihara, Y., Taniguchi, M., Watanabe, N., Hunter, T., & Osada, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307700101 · Cited by 472
Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation
O'Connell, M. J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.3.545 · Cited by 398
Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells
van Vugt, M. A. T. M., Brás, A., & Medema, R. H. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.07.015 · Cited by 385
G2 checkpoint abrogators as anticancer drugs
Kawabe, T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.513.3.4 · Cited by 377
Candolfi, M., Curtin, J. F., Nichols, W. S., Muhammad, A. G., King, G. D., Pluhar, G. E., McNiel, E. A., Ohlfest, J. R., Freese, A. B., Moore, P. F., et al. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9400-9 · Cited by 351
Fission yeast p107wee1 mitotic inhibitor is a tyrosine/serine kinase
Featherstone, C., & Russell, P. (1991) · Nature · doi:10.1038/349808a0 · Cited by 335
Hirose, Y., Berger, M. S., & Pieper, R. O. (2001) · PubMed · Cited by 333
Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., Recht, L. D., & Sikic, B. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1204 · Cited by 311
ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks
Lavin, M. F. (2007) · Oncogene · doi:10.1038/sj.onc.1210880 · Cited by 301
Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3
Sidi, S., Sanda, T., Kennedy, R. D., Hagen, A. T., Jette, C. A., Hoffmans, R., Pascual, J., Imamura, S., Kishi, S., Amatruda, J. F., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.037 · Cited by 297
Development of novel targeted therapies in the treatment of malignant glioma
Rich, J. N., & Bigner, D. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1380 · Cited by 247
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 240
Substrate Competition as a Source of Ultrasensitivity in the Inactivation of Wee1
Kim, S. Y., & Ferrell, J. E. (2007) · Cell · doi:10.1016/j.cell.2007.01.039 · Cited by 220
Nicholas, M. K., Lukas, R. V., Jafri, N. F., Faoro, L., & Salgia, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0874 · Cited by 214
Lee, Y., Scheck, A. C., Cloughesy, T. F., Lai, A., Dong, J., Farooqi, H. K., Liau, L. M., Horvath, S., Mischel, P. S., & Nelson, S. F. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-52 · Cited by 208
Cyclins and Cyclin–Dependent Kinases: Comparative Study of Hepatocellular Carcinoma Versus Cirrhosis
Masaki, T., Shiratori, Y., Rengifo, W., Igarashi, K., Yamagata, M., Kurokohchi, K., Uchida, N., Miyauchi, Y., Yoshiji, H., Watanabe, S., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50112 · Cited by 207
Lessons learned in the development of targeted therapy for malignant gliomas
Omuro, A. M. P., Faivre, S., & Raymond, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0047 · Cited by 196
Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
Hamer, P. C. D. W. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop068 · Cited by 166
Katayama, K., Fujita, N., & Tsuruo, T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5725-5737.2005 · Cited by 164
Hodgson, J., Yeh, R.-F., Ray, A., Wang, N. J., Smirnov, I. V., Yu, M., Hariono, S., Silber, J., Feiler, H. S., Gray, J. W., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-113 · Cited by 161
Nakano, I., Masterman-Smith, M. D., Saigusa, K., Paucar, A. A., Horvath, S., Shoemaker, L. D., Watanabe, M., Negro, A., Bajpai, R., Howes, A. L., et al. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21471 · Cited by 158
Kinomics: characterizing the therapeutically validated kinase space
Vieth, M., Sutherland, J. J., Robertson, D. H., & Campbell, R. M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03477-x · Cited by 157
Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis
Wang, Y., Decker, S. J., & Sebolt, J. S. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.697 · Cited by 155
Jäger, M., Dronkert, M. L., Modesti, M., Beerens, C. E., Kanaar, R., & van Gent, D. C. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.6.1317 · Cited by 152
The wee1 protein kinase is required for radiation-induced mitotic delay
Rowley, R., Hudson, J. D., & Young, P. G. (1992) · Nature · doi:10.1038/356353a0 · Cited by 150
The clinical significance of Cyclin B1 and Wee1 expression innon-small-cell lung cancer
Yoshida, T., Tanaka, S., Mogi, A., Shitara, Y., & Kuwano, H. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh073 · Cited by 144
Structure meets function—Centrosomes, genome maintenance and the DNA damage response
Löffler, H., Lukas, J., Bártek, J., & Krämer, A. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.06.008 · Cited by 131
Kotliarov, Y., Steed, M. E., Christopher, N., Walling, J., Su, Q., Heiss, J. D., Rosenblum, M., Mikkelsen, T., Zenklusen, J. C., & Fine, H. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1691 · Cited by 127
Kortmansky, J. S., Shah, M. A., Kaubisch, A., Weyerbacher, A. R., Yi, S., Tong, W. P., Sowers, R. S., Gönen, M., O'Reilly, E. M., Kemeny, N. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.116 · Cited by 112
Ravaud, A., Hawkins, R. E., Gardner, J. P., von der Maase, H., Zantl, N., Harper, P., Rolland, F., Audhuy, B., Machiels, J.-P., Pétavy, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5029 · Cited by 105
Agulnik, M., Santos, G. D. C., Hedley, D. W., Nicklee, T., Reis, P. P., Ho, J., Pond, G. R., Chen, H., Chen, S., Shyr, Y., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.6554 · Cited by 101
Elder, R. T., Yu, M., Chen, M., Zhu, X., Yanagida, M., & Zhao, Y. (2001) · Virology · doi:10.1006/viro.2001.1007 · Cited by 94
14-3-3 binding regulates catalytic activity of human Wee1 kinase.
Rothblum‐Oviatt, C., Ryan, C. E., & Piwnica-Worms, H. M. (2001) · PubMed · Cited by 88
Hashimoto, O., Shinkawa, M., Torimura, T., Nakamura, T., Selvendiran, K., Sakamoto, M., Koga, H., Ueno, T., & Sata, M. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-292 · Cited by 83
Claes, A., Schuuring, J., Boots‐Sprenger, S., Hendriks-Cornelissen, S. J. B., Dekkers, M. M. G., van der Kogel, A. J., Leenders, W. P. J., Wesseling, P., & Jeuken, J. W. M. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00141.x · Cited by 72
Self-citationLi, J., Wang, Y., Sun, Y., & Lawrence, T. S. (2002) · Radiation Research · doi:10.1667/0033-7587(2002)157[0322:wttigp]2.0.co;2 · Cited by 55
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma
Bhat, K. P. L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J. D., Goodman, L. D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.001 · Cited by 1,102
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Recent advances in the molecular understanding of glioblastoma
Bleeker, F. E., Molenaar, R. J., & Leenstra, S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0793-0 · Cited by 456
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaih, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 441
Metadata
- Authors
- Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., Peter Vandertop, W., Cloos, J., Tannous, B. A., Wesseling, P., Aten, J. A., Noske, D. P., Van Noorden, C. J. F., & Würdinger, T.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 18
- Issue
- 3
- Pages
- 244-257
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2039442869
- Cited by
- 294
- References
- 65
- FWCI
- 7.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.